Pharmaceuticals, Biotechnology and Life Sciences
Mylan has agreed to the terms of a global settlement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. related to patents for Herceptin (trastuzumab), which provides Mylan with global licenses for its trastuzumab product.
iShares NASDAQ Biotechnology exchange-traded fund has gained 13% so far this year, more than double the SPDR S&P 500 ETF’s 6.3% rise, as the potential for new drugs and mergers and acquisitions has rekindled interest in the beaten-down sector.
Data that should help unlock the sales potential of a potent new cholesterol medicine will be unveiled at the American College of Cardiology meeting this week as the future of the only rival drug rests with the courts in an ongoing patent dispute.
Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK, in coordination with fourteen other European regulatory agencies, has approved a new indication for Ipsen’s Decapeptyl as adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine-responsive early-stage breast cancer in women at high-risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy.
GenSight Biologics, a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, has reported €22.1 million loss for 2016, which is increase of loss comparing last years €13.7 million.
Virbac has reported net profit of €34.6 million for 2016 which is 268% increase compared to 2015.
TiGenix has found in its acute hearth attack study that allogenic cardiac stem cells can be transplanted safely through the coronary tree.
Innate Pharma and Bristol-Myers Squibb have modified the clinical trial protocol for its ongoing Phase I/II trial evaluating the safety and tolerability of lirilumab in combination with Opdivo in patients with advanced refractory solid tumors.
Mylan has launched Desvenlafaxine Extended-release Tablets, 50 mg and 100 mg, a generic version of Pfizer’s Pristiq Tablets in U.S..
The popularity of cannabis in its raw form will increasingly be priced as a commodity
Pharmaceutical Daily has conducted an interview with Duke Rodriguez, the CEO of Ultra Health, the company that has opened the first pharmaceutical cannabis factory in the USA.
The Ultra Health CEO answered questions about hurdles of a cannabis company, as most banks in the US cannot legally do business with such companies, and what is the new administration in the White House stand on legalizing cannabis.